Delivery of compounds with rehydrated blood cells

Abstract

Fixed-dried blood cells carrying an active agent are described, along with methods of making the same, methods of using the same, and compositions containing the same. The blood cells are preferably blood platelets.

That which is claimed is: 
     
         1 . Fixed-dried blood cells having an exogenous active agent coupled thereto, wherein said fixed-dried blood cells comprise fixed-dried blood platelets;
 wherein said exogenous active agent is selected from the group consisting of diagnostic agents and therapeutic agents;   wherein said active agent is coupled covalently to the interior or surface of said cells;   wherein said fixed-dried blood platelets are aldehyde fixed-dried blood platelets;   and wherein said fixed-dried blood platelets upon reconstitution: adhere to thrombogenic surfaces; undergo shape change upon adhering to a thrombogenic surface; and lead to the formation of a hemostatic plug upon adhering to a thrombogenic surface.   
     
     
         2 . The fixed-dried blood cells of  claim 1 , wherein said fixed-dried blood cells comprise mammalian fixed-dried blood cells. 
     
     
         3 . The fixed-dried blood cells of  claim 1 , wherein said fixed-dried blood cells comprise human fixed-dried blood cells. 
     
     
         4 . The fixed-dried blood cells of  claim 1 , wherein said active agent is contained within said cells. 
     
     
         5 . The fixed-dried blood cells of  claim 1 , wherein said fixed-dried blood cells are fixed-dried blood platelets which upon reconstitution:
 release their granular contents upon adhering to a thrombogenic surface.   
     
     
         6 . The fixed-dried blood cells of  claim 1 , wherein said active agent comprises an antiviral agent. 
     
     
         7 . The fixed-dried blood cells of  claim 1 , wherein said active agent comprises a blood coagulation protein. 
     
     
         8 . The fixed-dried blood cells of  claim 1 , wherein said active agent comprises a blood anti-coagulation protein. 
     
     
         9 . The fixed-dried blood cells of  claim 1 , wherein said active agent comprises a nucleic acid. 
     
     
         10 . The fixed-dried blood cells of  claim 1 , wherein said exogenous active agent is selected from the group consisting of detectable compounds, antiviral agents, blood coagulation proteins, blood anti-coagulation protein, and nucleic acids 
     
     
         11 . A pharmaceutical composition comprising:
 a pharmaceutically acceptable carrier; and   fixed-dried blood cells having an exogenous active agent coupled thereto, said fixed-dried blood cells rehydrated in said pharmaceutically acceptable carrier, wherein said fixed-dried blood cells comprise fixed-dried blood platelets;   wherein said exogenous active agent is selected from the group consisting of diagnostic agents and therapeutic agents;   wherein said active agent is coupled covalently to the interior or surface of said cells;   wherein said fixed-dried blood platelets are aldehyde fixed-dried blood platelets,   and wherein said fixed-dried platelets upon reconstitution:adhere to thrombogenic surfaces; undergo shape change upon adhering to a thrombogenic surface; and lead to the formation of a hemostatic plug upon adhering to a thrombogenic surface.   
     
     
         12 . The pharmaceutical composition of  claim 11 , wherein said carrier is a sterile carrier. 
     
     
         13 . The pharmaceutical composition of  claim 11 , wherein said carrier is a solid carrier. 
     
     
         14 . The pharmaceutical composition of  claim 11 , wherein said carrier is a liquid carrier. 
     
     
         15 . The pharmaceutical composition of  claim 11 , wherein said carrier is an aqueous carrier. 
     
     
         16 . The pharmaceutical composition of  claim 11 , wherein said fixed-dried blood cells comprise mammalian fixed-dried blood cells. 
     
     
         17 . The pharmaceutical composition of  claim 11 , wherein said fixed-dried blood cells comprise human fixed-dried blood cells. 
     
     
         18 . The pharmaceutical composition of  claim 11 , wherein said active agent is contained within said fixed-dried blood cells. 
     
     
         19 . The pharmaceutical composition of  claim 11 , wherein said fixed-dried blood cells are fixed-dried platelets which upon reconstitution:
 release their granular contents upon adhering to a thrombogenic surface.   
     
     
         20 . The pharmaceutical composition of  claim 11 , wherein said active agent comprises an antiviral agent. 
     
     
         21 . The pharmaceutical composition of  claim 11 , wherein said active agent comprises a blood coagulation protein. 
     
     
         22 . The pharmaceutical composition of  claim 11 , wherein said active agent comprises a blood anti-coagulation protein. 
     
     
         23 . The pharmaceutical composition of  claim 11 , wherein said active agent comprises a nucleic acid. 
     
     
         24 . The pharmaceutical composition of  claim 11 , wherein said exogenous active agent is selected from the group consisting of detectable compounds, antiviral agents, blood coagulation proteins, blood anti-coagulation protein, and nucleic acids. 
     
     
         25 . A method of making fixed-dried blood cells having an exogenous active agent coupled thereto, comprising:
 providing fixed blood cells, said fixed blood cells comprising fixed blood platelets;   coupling said exogenous active agent covalently to the interior or surface of said fixed blood cells; and   drying said fixed blood cells to produce fixed-dried blood cells carrying said active agent;   wherein said exogenous active agent is selected from the group consisting of diagnostic agents and therapeutic agents;   wherein said fixed-dried blood platelets are aldehyde fixed-dried blood platelets,   and wherein said fixed-dried blood platelets upon reconstitution: adhere to thrombogenic surfaces; undergo shape change upon adhering to a thrombogenic surface; and lead to the formation of a hemostatic plug upon adhering to a thrombogenic surface.   
     
     
         26 . The method of  claim 25 , wherein said fixed-dried blood cells carrying said active agent are rehydrated in a pharmaceutically acceptable carrier to provide a pharmaceutically acceptable composition comprising rehydrated fixed-dried blood cells carrying said active agent. 
     
     
         27 . The method of  claim 25 , wherein said fixed blood cells comprise fixed mammalian blood cells. 
     
     
         28 . The method of  claim 25 , wherein said fixed blood cells comprise fixed human blood cells. 
     
     
         30 . The method of  claim 25 , wherein said associating step is carried out by covalently or non-covalently coupling said active agent to said fixed blood cells. 
     
     
         31 . The method of  claim 25 , wherein said associating step is carried out by introducing said active agent into said fixed blood cells. 
     
     
         32 . The method of  claim 25 , wherein said rehydrated fixed-dried blood cells comprise rehydrated fixed-dried blood platelets which:
 release their granular contents upon adhering to a thrombogenic surface.   
     
     
         33 . The method according to  claim 25 , wherein said exogenous active agent is selected from the group consisting of detectable compounds, antiviral agents, blood coagulation proteins, blood anti-coagulation protein, and nucleic acids.